New research in the FASEB Journal suggests the protein Ddi 1 from Leishmania parasites is sensitive to
anti-HIV inhibitors and could be target for malaria and other parasitic diseases
2-May-2011 - Scientists have discovered that drugs used to treat HIV may also one day become
lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria. According to new research published
in The FASEB Journal ( http://www.fasebj.org ),
scientists have identified the target of action for some anti-HIV drugs with known abilities to kill serious
pathogenic parasites. While scientists have long known that these HIV drugs can kill parasites, exactly
how they work was previously unknown. Researchers discovered that a particular protein called Ddi 1
from Leishmania parasites is sensitive to anti-HIV inhibitors. This research could one day
significantly change the treatment of parasitic diseases.
"People in developing countries can be exposed to parasitic diseases such as malaria and
leishmaniasis that can kill millions of people, so new and effective drugs are urgently needed to combat these
infections," said Colin Berry, Ph.D., a researcher involved in the work from the Cardiff School of
Biosciences at Cardiff University in Cardiff in the United Kingdom. "The use of existing
anti-HIV agents has indicated that there is a potential target in some parasites and by
identifying the protein responsible, we hope to exploit this weakness in the parasite
to develop new and effective therapeutics to combat these devastating diseases."
Scientists studied yeast that lacked the Ddi 1 protein and found that high levels of proteins
were secreted. The addition of the Leishmania Ddi 1 protein returned the yeast to normal low secretion levels until HIV
proteinase inhibitors were added. These inhibitors blocked the ability of Leishmania Ddi 1 to reduce secretions and
showed that the Ddi 1 protein interacted with the drugs. Additionally, when researchers used human Ddi 1, they
identified drugs that were good at blocking the activity of the Leishmania protein, but which were much
weaker against the human equivalent, suggesting that possible side effects in a future drug could be
reduced. Study data support the potential use of this class of compounds for leishmaniasis, but do
not yet support the use of existing marketed compounds in a clinical context. The potency of the
existing compounds indicates that they may be a useful start point for further exploratory chemistry.
"Like HIV, parasitic diseases have been and still are a serious threat to human health
world-wide," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Millions die each year
from these maladies and we desperately need new drugs. How fortuitous that agents designed against one killer,
HIV, may now be turned against parasitic diseases such as leishmaniasis and malaria."
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at
http://www.faseb.org/fjupdate.aspx. The FASEB Journal ( http://www.fasebj.org ) is
published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association
as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists
and engineers to improve-through their research-the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological
and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Rhian E. White, David J. Powell, and Colin Berry. HIV proteinase inhibitors target the Ddi1-like protein of Leishmania
parasites. FASEB J May 2011 25:1729-1736; doi:10.1096/fj.10-178947 ; http://www.fasebj.org/content/25/5/1729.abstract
Contact: Cody Mooneyhan
Federation of American Societies for Experimental Biology